Welcome to our dedicated page for Faeth Therapeutics news (Ticker: FTH), a resource for investors and traders seeking the latest updates and insights on Faeth Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Faeth Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Faeth Therapeutics's position in the market.
Faeth Therapeutics (FTH) appointed renowned cancer biologist and company scientific co‑founder Karen Vousden, Ph.D., to its Board of Directors, effective September 11, 2026, as the company approaches topline Phase 2 data for its all‑oral PIKTOR program in endometrial cancer.
Vousden is noted for work on the p53 tumor suppressor and tumor metabolic dependencies, and has led research organizations including the Francis Crick Institute and Cancer Research UK’s Beatson Institute. She has served on the board of Bristol Myers Squibb since 2018 and holds fellowships in multiple major scientific academies. Vousden described PIKTOR’s multi‑node inhibition of the PI3K/AKT/mTOR pathway as a rational approach and said she is delighted to join the board.
Faeth Therapeutics (FTH) will host a virtual KOL event on October 6, 2026 to discuss endometrial cancer.
The 10:00 AM ET webcast will feature Marcus Goncalves, MD, PhD, and company management reviewing the PAM (PI3K/AKT/mTOR) pathway, Faeth’s investigational multi-node inhibitor PIKTOR, and its ongoing Phase 2 endometrial cancer trial. Topics include comparison with single-node inhibition, rationale for PIKTOR’s current dose and schedule, prior Phase 1b clinical data, and the unmet need after checkpoint inhibitors. Topline Phase 2 data are anticipated by year-end, followed by a live Q&A session.
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node cancer therapies including lead program PIKTOR, announced management’s participation in multiple September 2026 investor conferences.
Events include Wells Fargo, Citi, Cantor, Morgan Stanley, Baird, H.C. Wainwright, and Deutsche Bank conferences across Boston and New York, featuring fireside chats, 1x1 meetings, and webcasts.
Faeth Therapeutics (Nasdaq: FTH) reported that its Board’s Compensation Committee granted stock options to three new employees for an aggregate of 94,000 shares of common stock, effective August 25, 2026, as inducement awards under the company’s 2026 Inducement Plan and in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $34.52 per share, equal to Faeth’s closing share price on the grant date. According to the company, 25% of each award vests on the employee’s first service anniversary, with the remaining shares vesting in 36 substantially equal monthly installments, subject to continued service. The options have a 10-year term and are governed by the 2026 Inducement Plan and applicable award agreements.
Faeth Therapeutics (Nasdaq: FTH) reported that the U.S. Food and Drug Administration has granted Fast Track designation for its lead program PIKTOR, the combination of sapanisertib and serabelisib, together with paclitaxel. The designation covers treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and who have previously received platinum-based chemotherapy and an immune checkpoint inhibitor.
According to Faeth Therapeutics, PIKTOR is being evaluated in an ongoing Phase 2 trial in second-line advanced endometrial cancer, known as Study FTH-PIK-201, with topline data expected by year-end 2026. The company highlights the unmet medical need in this biomarker-selected, previously treated patient population and notes preclinical data suggesting that PIKTOR may resensitize tumors to chemotherapy.
Faeth Therapeutics (Nasdaq: FTH) announced two senior leadership appointments as it prepares for upcoming PIKTOR clinical milestones. Deepak Tiwari was named Senior Vice President, Technical Operations, and will oversee chemistry, manufacturing and controls (CMC) and supply chain activities supporting PIKTOR’s clinical development and potential future commercialization.
Matt Biegler was appointed Senior Vice President, Investor Relations, leading engagement with current and prospective investors. Tiwari brings about 30 years of biopharmaceutical experience across CMC, technical operations, manufacturing and supply chain at multiple global and specialty companies, while Biegler joins from Oppenheimer & Co. after a career in biotechnology equity research and earlier roles in clinical research operations.
Faeth Therapeutics (Nasdaq: FTH) announced that its Board’s Compensation Committee granted inducement stock options to two new employees for an aggregate of 11,000 shares of common stock. The options were granted effective August 4, 2026 under the company’s 2026 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $25.50 per share, equal to the closing price on the grant date, and a 10‑year term. Vesting covers 25% of each award on the first anniversary of the employee’s start date, with the remaining 75% vesting in 36 substantially equal monthly installments, subject to continued service and the applicable plan and award agreements.
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company, will present translational and pharmacokinetic/pharmacodynamic (PK/PD) data for PIKTOR, its all-oral multi-node PI3K/AKT/mTOR pathway inhibitor combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) in New York on August 8.
The poster, titled “Exposure/Response Analysis of an Oral Multi-Node PI3K/AKT/mTOR Pathway Inhibitor Combination of Serabelisib and Sapanisertib” (Poster #9), will be presented between 10:25 and 11:30 AM at the New York Marriott Marquis. According to Faeth Therapeutics, PK/PD analysis integrating skin biopsy data and pharmacokinetic modeling from earlier third-party clinical trials informed selection of the recommended Phase 2 PIKTOR dose: 3 mg sapanisertib and 200 mg serabelisib three days per week for the ongoing Phase 2 second-line advanced endometrial cancer trial, Study FTH-PIK-201 (NCT06463028). A copy of the poster will be available in the Investors section of the company’s website at the start of the poster session.
Faeth Therapeutics (Nasdaq: FTH) reported Q2 2026 cash, cash equivalents and marketable securities of $186.4 million as of June 30, 2026, up from $21.2 million at December 31, 2025, supported by a concurrent $200 million PIPE financing completed with its combination with Sensei Biotherapeutics.
The company is advancing PIKTOR, dosing the first patient in April in its Phase 1b/2 PIK-101 trial for HR+/HER2- advanced breast cancer and targeting year-end 2026 topline Phase 2 PIK-201 data in endometrial cancer. Q2 R&D and G&A expenses each rose to $9.2 million, and net loss widened to $16.0 million. Faeth changed its name and ticker to FTH in June and refreshed leadership and its board.
Faeth Therapeutics (Nasdaq: FTH) granted stock options to two new employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4). The awards cover an aggregate of 25,500 shares of common stock, granted on July 20, 2026 at an exercise price of $28.19 per share, equal to the closing market price that day. The options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 36 substantially equal monthly installments, subject to continued service.